Effect of pharmacist-led patient education on adherence to tuberculosis treatment

American Journal of Health-System Pharmacy

Volumn 64, Issue 5, 2007, Pages 497-506

  Clark, Philip M ^a   Karagoz, Turan ^b   Apikoglu Rabus, Sule ^c   Izzettin, Fikret Vehbi ^c  

^a YEDITEPE UNIVERSITY   (Turkey)

^b Sureyyapasa Chest Diseases and Thoracic Surgery Teaching Hospital   (Turkey)

^c MARMARA UNIVERSITY   (Turkey)

Author keywords

Antituberculars; Clinical pharmacists; Compliance; Isoniazid; Patient information; Patients; Pharmaceutical care; Rational therapy; Resistance; Tuberculosis

Indexed keywords

AMIKACIN; AMINOGLYCOSIDE; AMINOSALICYLIC ACID; ANTACID AGENT; ANTITUSSIVE AGENT; BRONCHODILATING AGENT; CAPREOMYCIN; CHOLINERGIC RECEPTOR BLOCKING AGENT; CYCLOSERINE; DRUG METABOLITE; ETHAMBUTOL; ETHIONAMIDE; GENTAMICIN; ISONIAZID; NONSTEROID ANTIINFLAMMATORY AGENT; PROTIONAMIDE; PYRAZINAMIDE; PYRIDOXINE; QUINOLINE DERIVED ANTIINFECTIVE AGENT; RIFAMPICIN; STREPTOMYCIN; SULFONYLUREA;

ADULT; ANALGESIA; ANOREXIA; ARTHRALGIA; ARTICLE; CASE CONTROL STUDY; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEPRESSION; DIZZINESS; DRUG MONITORING; FEMALE; GASTROINTESTINAL SYMPTOM; HEADACHE; HEALTH CARE NEED; HEARING LOSS; HUMAN; HYPERURICEMIA; INSOMNIA; MAJOR CLINICAL STUDY; MALE; MULTIDRUG RESISTANCE; MYALGIA; NAUSEA; NEURITIS; NURSING CARE; OTOTOXICITY; PARESTHESIA; PATIENT CARE; PATIENT COMPLIANCE; PATIENT EDUCATION; PATIENT MONITORING; PERIPHERAL NEUROPATHY; PHARMACIST; PRESCRIPTION; PRIORITY JOURNAL; PSYCHOSIS; RANDOMIZED CONTROLLED TRIAL; RESPIRATION CONTROL; SMOKING; TASTE DISORDER; TUBERCULOSIS; URINALYSIS; VOMITING;

EID: 33847397374     PISSN: 10792082     EISSN: None     Source Type: Journal    
DOI: 10.2146/ajhp050543     Document Type: Article

References (57)

1. Corbett EL, Watt CJ, Walker N et al. The growing burden of tuberculosis: global trends and interactions with the HIV epidemic. Arch Intern Med. 2003; 163:1009-21.
2. Lauzardo M, Ashkin D. Phthisiology at the dawn of the new century. Chest. 2000; 117:1455-73.
3. Pablos-Mendez A, Raviglione MC, Laszlo A. Global surveillance for antituberculosis drug resistance 1994-1997. N Engl J Med. 1998; 338:1641-9.
4. Elzinga G, Raviglione MC, Maher D. Scale up: meeting targets in global tuberculosis control. Lancet. 2004; 363:814-9.
5. World Health Organization. Tuberculosis-fact sheet no. 104. Geneva: World Health Organization; 2006.
6. Maher D, Uplekar M, Blanc L et al. Treatment of tuberculosis. BMJ. 2003; 327:822-3.
7. Blumberg HM, Burman WJ, Chaisson RE et al. American Thoracic Society, Centers for Disease Control and Prevention and the Infectious Diseases Society. Treatment of tuberculosis. Am J Respir Crit Care Med. 2003; 167:603-62.
8. Pilheu JA. Tuberculosis 2000: problems and solutions. Int J Tuber Dis. 1998; 2:696-703.
9. Balci I, Dikensoy O, Bayram A et al. Drug-resistant tuberculosis at the University Hospital in Gaziantep, south-eastern Turkey. J Int Med Res. 2000; 28:300-6.
10. Kays MB. Tuberculosis. In: Koda-Kimble MA, Young LY, Kradjan WA et al., eds. Applied therapeutics. 8th ed. Baltimore: Lippincott, Williams & Wilkins; 2005:1-26.
11. Hand K. Tuberculosis: pharmacological management. Hosp Pharm. 2006; 13:81-5.
12. Haynes RB, McDonald H, Garg AX et al. Interventions for helping patients to follow prescriptions for medications. Cochrane Database Syst Rev. 2002; 2:CD000011.
13. Taylor HG. The tuberculosis epidemic and the pharmacist's role. Am Pharm. 1992; 32:577.
14. Nichols-English G, Poirier S. Optimizing adherence to pharmaceutical care plans. J Am Pharm Assoc. 2000; 40:475-85.
15. Cohen F. Adherence to therapy in tuberculosis. Ann Rev Nurse Res. 1997; 15:153-84.
16. Sbarbaro J, Blomberg B, Chaulet P. Fixed dose combination formulations for tuberculosis treatment. Int J Tuberc Lung Dis. 1999; 3(suppl):S286-8.
17. Tuberculosis Coalition for Technical Assistance. International standards for tuberculosis care (ISTC). The Hague: Tuberculosis Coalition for Technical Assistance; 2006.
18. World Health Organization. Treatment of tuberculosis: guidelines for national programmes. 3rd ed. Geneva: World Health Organization; 2003.
19. Morisky DE, Malotte CK, Choi P et al. A patient education program to improve adherence rates with antituberculosis drug regimens. Health Educ Q. 1990; 17:253-67.
20. Chan ED, Iseman MD. Current medical treatment for tuberculosis. BMJ. 2002; 325:1282-6.
21. Dye C, Garnett GP, Sleeman K et al. Prospects for worldwide tuberculosis control under the WHO DOTS strategy. Lancet. 1998; 352:1886-91.
22. Grange JM, Zumla A. Making DOTS succeed. Lancet. 1997; 350:157.
23. Ormerod LP. DOT for tuberculosis: why, when, how and if? Thorax. 1999; 54(suppl 2):S42-5.
24. Elles SL, Billups SJ, Malone DC. Types of interventions made by clinical pharmacists in the IMPROVE study. Pharmacotherapy. 2000; 20:429-35.
25. Schmock GT, Michaud J, Guenette AJ. Reengineering an opportunity to advance clinical practice in a community hospital. Am J Health-Syst Pharm. 1999; 56:1945-9.
26. Gourley DR, Gourley GA, Solomon DK. Part 1: development, interpretation and evaluation of a multicenter pharmaceutical care outcomes study. J Am Pharm Assoc. 1998; 38:567-73.
27. Strand LM, Guerrero RM, Nickman NA et al. Integrated patient specific model of pharmacy practice. Am J Hosp Pharm. 1990; 47:550-4.
28. Building a practice in pharmaceutical care. Pharm J. 1998; 260:874-6.
29. USP DI: drug information for the health care professional. 21st ed. Rockville, MD: United States Pharmacopeial Convention; 2001.
30. Schraufnagel DE, Stoner R, Whiting E et al. Testing for isoniazid: an evaluation of the Arkansas method. Chest. 1990; 98:314-6.
31. Kilburn JO, Beam RE, David HL et al. Reagent-impregnated paper strip for detection of metabolic products of isoniazid in urine. Am Rev Respir Dis. 1972; 106:923-4.
32. Perry S, Hovell MF, Blumberg E et al. Urine testing to monitor adherence to TB preventive therapy. J Clin Epidemiol 2002; 55:235-8.
33. Salleras Sanmarti L, Alcaide Megias J, Altet Gomez MN et al. Evaluation of the efficacy of health education on the compliance with antituberculosis chemoprophylaxis in school children. A randomized clinical trial. Tuber Lung Dis. 1993; 74:28-31.
34. Leuenberger P, Sonntag R. Drugs used in tuberculosis and leprosy. In: Dukes MN, Aronson JK, eds. Meyler's side effects of drugs: an encyclopedia of adverse reactions and interactions. 14th ed. Amsterdam: Elsevier; 2000.
35. Stockley IH, ed. Stockley's drug interactions. 6th ed. London: Pharmaceutical Press; 2002.
36. Haynes RB, Yao X, Degani A et al. Interventions for enhancing medication adherence. Cochrane Database Syst Rev. 2005; 4:CD000011.
37. Abal AT, Jayakrishnan B, Parwer S et al. Effect of cigarette smoking on sputum smear conversion in adults with active pulmonary tuberculosis. Respir Med. 2005; 99:415-20.
38. No Smoking Day: what pharmacists can do to help smokers kick the habit. Pharm J. 2006; 276:161-2.
39. Grosso A, Jani Y, Minton J. Tuberculosis chemotherapy in the UK. Pharm J. 2004; 273:366-8.
40. Zeind CS, Gourley GK, Chandler-Toufieli DM. Tuberculosis. In: Herfindal ET, Gourley DR, eds. Textbook of therapeutics. 7th ed. Baltimore, MD: Lippincott Williams & Wilkins; 2000:1427-50.
41. Lacy CF, Armstrong LL, Goldman MP et al., eds. Drug information handbook, 11th ed. Hudson, OH: Lexi-Comp; 2002.
42. O-Lee T, Stewart CE IV, Seery L et al. Fluoroquinolone-induced arthralgia and myalgia in the treatment of sinusitis. Am J Rhinol. 2005; 19:395-9.
43. Skinner HB. Acute pain management: new approaches. Hosp Pharm. 2004; 16:54-5.
44. Tackling chronic pain with pharmacistled clinic. Pharm J. 2005; 275:15.
45. Gbayismore A, Lardizabul AA, Reichman LB. Update: prevention and treatment of tuberculosis. Curr Opin Inf Dis. 2000; 13:155-9.
46. Karyadi E, West CE, Schultink W et al. A double-blind, placebo-controlled study of vitamin A and zinc supplementation in persons with tuberculosis in Indonesia: effects on clinical response and nutritional status. Am J Clin Nutr. 2002; 75:720-7.
47. Yew WW, Chan CK, Leung CC et al. Comparative roles of levofloxacin and ofloxacin in the treatment of multidrug resistant tuberculosis. Chest. 2003; 124:1476-81.
48. Frieden TR, Sterling TR, Munsiff SS et al. Tuberculosis. Lancet. 2003; 362:887-99.
49. Small PM, Fujiwara PI. Management of tuberculosis in the United States. N Engl J Med. 2001; 345:189-200.
50. Clifford RM, Davis WA, Batty KT et al. Effect of a pharmaceutical care program on vascular risk factors in type 2 diabetes. The Fremantle Diabetes Study. Diabetes Care. 2005; 28:771-6.
51. Minton J, Yogini J, Grosso A. Treating drug resistant tuberculosis. Pharm J. 2004; 273:422-44.
52. Tahaoglu K, Torun T, Sevim T. The treatment of multidrug resistant tuberculosis in Turkey. N Engl J Med. 2001; 345:170-4.
53. Yew WW. Therapeutic drug monitoring in antituberculosis chemotherapy: clinical perspectives. Clin Chim Acta. 2001; 313:31-6.
54. Farmer P, Furin J, Shin S. Managing multidrug-resistant tuberculosis. J Res Dis. 2000; 21:53-6.
55. Dayton CS. Pharmacist involvement in a tuberculosis outpatient clinic. Am J Hosp Pharm. 1978; 35:708-10.
56. Kanyok TP. Combating tuberculosis. Am J Health-Syst Pharm. 1997; 54:375. Editorial.
57. Coleman LT, Adams NC, Gong WC. Pharmacist as a primary care provider in a tuberculosis clinic. Am J Hosp Pharm. 1983; 40:278-81.